



Back to results | 1 of 1

Export Download Print E-mail Save to PDF Add to List More... >

[Full Text](#) | View at Publisher**Document type**

Article

Source type

Journal

ISSN

00278424

DOI

10.1073/pnas.2010053118

Publisher

National Academy of Sciences

CODEN

PNASA

Original language

English

PubMed ID

34312224

View less ^

Proceedings of the National Academy of Sciences of the United States of America • Volume 118, Issue 31 • 3 August 2021 • Article number e2010053118

PIP4Ks impact on PI3K, FOXP3, and UHRF1 signaling and modulate human regulatory T cell proliferation and immunosuppressive activity

Poli A.^{a, b} , Abdul-Hamid S.^{c, d}, Zaurito A.E.^{b, e}, Campagnoli F.^{b, c, f}, Bevilacqua V.^b, Sheth B.^c, Fiume R.^g,

Pagani M.^{a, h}, Abrignani S.^{b, i}, Divecha N.^{b, c}

Save all to author list

^a Italian Foundation for Cancer Research Institute of Molecular Oncology, Milan, 20139, Italy

^b National Institute of Molecular Genetics "Romeo ed Enrica Invernizzi", Milan, 20122, Italy

^c Inositide Laboratory, School of Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, SO17 1BJ, United Kingdom

^d Department of Basic Medical Science, Faculty of Nursing, International Islamic University Malaysia, Kuantan, 25200, Malaysia

View additional affiliations

Abstract**Author keywords****Reaxys Chemistry database information****SciVal Topics****Metrics****Funding details****Abstract**

Regulatory T cells (Tregs) play fundamental roles in maintaining peripheral tolerance to prevent autoimmunity and limit legitimate immune responses, a feature hijacked in tumor microenvironments in which the recruitment of Tregs often extinguishes immune surveillance through suppression of T-effector cell signaling and tumor cell killing. The pharmacological tuning of Treg activity without impacting on T conventional (Tconv) cell activity would likely be beneficial in the treatment of various human pathologies. PIP4K2A, 2B, and 2C constitute a family of lipid kinases that phosphorylate PtdIns5P to PtdIns(4,5)P2. They are involved in stress signaling, act as synthetic lethal targets in p53-null tumors, and in mice, the loss of PIP4K2C leads to late onset hyperinflammation. Accordingly, a human single

Cited by 0 documents

Inform me when this document is cited in Scopus:

[Set citation alert >](#)

Related documents

Pharmacological inhibition of PI5P4K β disrupts cell energy metabolism and selectively kills p53-null tumor cells

Chen, S. , Tjin, C.C. , Gao, X. (2021) *Proceedings of the National Academy of Sciences of the United States of America*

Emerging cell biological functions of phosphatidylinositol 5 phosphate 4 kinase

Raghu, P. (2021) *Current Opinion in Cell Biology*

Phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4K γ), a lipid signalling enigma

Giudici, M.-L. , Clarke, J.H. , Irvine, R.F. (2016) *Advances in Biological Regulation*

View all related documents based on references

Find more related documents in Scopus based on:

Authors > Keywords >

nucleotide polymorphism (SNP) near the PIP4K2C gene is linked with susceptibility to autoimmune diseases. How PIP4Ks impact on human T cell signaling is not known. Using ex vivo human primary T cells, we found that PIP4K activity is required for Treg cell signaling and immunosuppressive activity. Genetic and pharmacological inhibition of PIP4K in Tregs reduces signaling through the PI3K, mTORC1/S6, and MAPK pathways, impairs cell proliferation, and increases activation-induced cell death while sparing Tconv. PIP4K and PI3K signaling regulate the expression of the Treg master transcriptional activator FOXP3 and the epigenetic signaling protein Ubiquitin-like containing PHD and RING finger domains 1 (UHRF1). Our studies suggest that the pharmacological inhibition of PIP4K can reprogram human Treg identity while leaving Tconv cell signaling and T-helper differentiation to largely intact potentially enhancing overall immunological activity. © 2021 National Academy of Sciences. All rights reserved.

Author keywords

Immunosuppression; Phosphatidylinositol 5-phosphate 4-kinase; Phosphoinositide kinases; T-regulatory cells; UHRF1

Reaxys Chemistry database information

Substances

[View all substances \(1\)](#)

```
{"fill-  
opacity": "1", "color-  
rendering": "auto", "color-  
interpolation": "auto", "text-  
rendering": "auto", "stroke": "black", "stroke-  
Width": 2, "stroke-  
Linecap": "square", "width": 200, "stroke-  
Miterlimit": 10, "shape-  
Type": "square"}
```

Powered by [Reaxys](#)

SciVal Topics

Metrics

Funding details

References (60)

[View in search results format >](#)

All [Export](#)  [Print](#)  [E-mail](#)  [Save to PDF](#) [Create bibliography](#)

- 1 Luckheeram, R.V., Zhou, R., Verma, A.D., Xia, B.
[CD4⁺T cells: Differentiation and functions \(Open Access\)](#)
(2012) *Clinical and Developmental Immunology*, 2012, art. no. 925135. Cited 455 times.
doi: 10.1155/2012/925135
[View at Publisher](#)
- 2 Josefowicz, S.Z., Lu, L.-F., Rudensky, A.Y.
[Regulatory T cells: Mechanisms of differentiation and function \(Open Access\)](#)
(2012) *Annual Review of Immunology*, 30, pp. 531-564. Cited 1692 times.
doi: 10.1146/annurev.immunol.25.022106.141623
[View at Publisher](#)
- 3 Li, M.O., Rudensky, A.Y.
[T cell receptor signalling in the control of regulatory T cell differentiation and function \(Open Access\)](#)
(2016) *Nature Reviews Immunology*, 16 (4), pp. 220-233. Cited 223 times.
<http://www.nature.com/nri/index.html>
doi: 10.1038/nri.2016.26
[View at Publisher](#)
- 4 Sakaguchi, S., Yamaguchi, T., Nomura, T., Ono, M.
[Regulatory T Cells and Immune Tolerance \(Open Access\)](#)
(2008) *Cell*, 133 (5), pp. 775-787. Cited 3225 times.
doi: 10.1016/j.cell.2008.05.009
[View at Publisher](#)

- 5 Vignal, D.A.A., Collison, L.W., Workman, C.J.
How regulatory T cells work ([Open Access](#))
(2008) *Nature Reviews Immunology*, 8 (7), pp. 523-532. Cited 1923 times.
doi: 10.1038/nri2343
[View at Publisher](#)
-
- 6 Gottschalk, R.A., Corse, E., Allison, J.P.
TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo ([Open Access](#))
(2010) *Journal of Experimental Medicine*, 207 (8), pp. 1701-1711. Cited 195 times.
<http://jem.rupress.org/content/207/8/1701.full.pdf+html>
doi: 10.1084/jem.20091999
[View at Publisher](#)
-
- 7 Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., (...), Sakaguchi, S.
Functional Delineation and Differentiation Dynamics of Human CD4⁺ T Cells Expressing the FoxP3 Transcription Factor ([Open Access](#))
(2009) *Immunity*, 30 (6), pp. 899-911. Cited 1449 times.
doi: 10.1016/j.jimmuni.2009.03.019
[View at Publisher](#)
-
- 8 Walker, M.R., Kasprowicz, D.J., Gersuk, V.H., Bénard, A., Van Landeghen, M., Buckner, J.H., Ziegler, S.F.
Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4⁺CD25⁻ T cells ([Open Access](#))
(2003) *Journal of Clinical Investigation*, 112 (9), pp. 1437-1443. Cited 1046 times.
doi: 10.1172/JCI200319441
[View at Publisher](#)
-
- 9 Hori, S., Nomura, T., Sakaguchi, S.
Control of regulatory T cell development by the transcription factor Foxp3
(2003) *Science*, 299 (5609), pp. 1057-1061. Cited 6325 times.
doi: 10.1126/science.1079490
[View at Publisher](#)
-
- 10 Fontenot, J.D., Gavin, M.A., Rudensky, A.Y.
Foxp3 programs the development and function of CD4⁺CD25⁺ regulatory T cells
(2003) *Nature Immunology*, 4 (4), pp. 330-336. Cited 5704 times.
doi: 10.1038/ni904
[View at Publisher](#)
-
- 11 Wildin, R.S., Ramsdell, F., Peake, J., Faravelli, F., Casanova, J.-L., Buist, N., Levy-Lahad, E., (...), Brunkow, M.E.
X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy
(2001) *Nature Genetics*, 27 (1), pp. 18-20. Cited 1383 times.
doi: 10.1038/83707
[View at Publisher](#)
-
- 12 Chen, C., Rowell, E.A., Thomas, R.M., Hancock, W.W., Wells, A.D.
Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histone acetylation ([Open Access](#))
(2006) *Journal of Biological Chemistry*, 281 (48), pp. 36828-36834. Cited 171 times.
<http://www.jbc.org/cgi/reprint/281/48/36828>
doi: 10.1074/jbc.M608848200
[View at Publisher](#)
-

- 13 Tanaka, A., Sakaguchi, S.
Regulatory T cells in cancer immunotherapy ([Open Access](#))
(2017) *Cell Research*, 27 (1), pp. 109-118. Cited 529 times.
<http://www.nature.com/cr/index.html>
doi: 10.1038/cr.2016.151
[View at Publisher](#)
-
- 14 Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., (...), Zou, W.
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
(2004) *Nature Medicine*, 10 (9), pp. 942-949. Cited 3759 times.
doi: 10.1038/nm1093
[View at Publisher](#)
-
- 15 Patton, D.T., Garden, O.A., Pearce, W.P., Clough, L.E., Monk, C.R., Leung, E., Rowan, W.C., (...), Okkenhaug, K.
Cutting edge: The phosphoinositide 3-kinase p110 δ is critical for the function of CD4 $^{+}$ CD25 $^{+}$ Foxp3 $^{+}$ regulatory T cells ([Open Access](#))
(2006) *Journal of Immunology*, 177 (10), pp. 6598-6602. Cited 238 times.
<http://www.jimmunol.org/>
doi: 10.4049/jimmunol.177.10.6598
[View at Publisher](#)
-
- 16 Ali, K., Soond, D.R., Piñeiro, R., Hagemann, T., Pearce, W., Lim, E.L., Bouabe, H., (...), Vanhaesbroeck, B.
Inactivation of PI(3)K p110 δ breaks regulatory T-cell-mediated immune tolerance to cancer ([Open Access](#))
(2014) *Nature*, 510 (7505), pp. 407-411. Cited 323 times.
<http://www.nature.com/nature/index.html>
doi: 10.1038/nature13444
[View at Publisher](#)
-
- 17 Chellappa, S., Kushekhar, K., Munthe, L.A., Tjønnfjord, G.E., Aandahl, E.M., Okkenhaug, K., Taskén, K.
The PI3K p110d isoform inhibitor idelalisib preferentially inhibits human regulatory T cell function ([Open Access](#))
(2019) *Journal of Immunology*, 202 (5), pp. 1397-1405. Cited 65 times.
<http://www.jimmunol.org/content/jimmunol/202/5/1397.full.pdf>
doi: 10.4049/jimmunol.1701703
[View at Publisher](#)
-
- 18 Rameh, L.E., Tolias, K.F., Duckworth, B.C., Cantley, L.C.
A new pathway for synthesis of phosphatidylinositol-4,5-bisphosphate
(1997) *Nature*, 390 (6656), pp. 192-196. Cited 345 times.
doi: 10.1038/36621
[View at Publisher](#)
-
- 19 Bultsma, Y., Keune, W.-J., Divecha, N.
PIP4K β interacts with and modulates nuclear localization of the high-activity PtdIns5 P-4-kinase isoform PIP4K α
(2010) *Biochemical Journal*, 430 (2), pp. 223-235. Cited 57 times.
<http://www.biochemj.org/bj/430/0223/4300223.pdf>
doi: 10.1042/BJ20100341
[View at Publisher](#)
-

- 20 Gozani, O., Karuman, P., Jones, D.R., Ivanov, D., Cha, J., Lugovskoy, A.A., Baird, C.L., (...), Yuan, J.
The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor ([Open Access](#))
(2003) *Cell*, 114 (1), pp. 99-111. Cited 406 times.
<https://www.sciencedirect.com/journal/cell>
doi: 10.1016/S0092-8674(03)00480-X
[View at Publisher](#)
-
- 21 Jones, D.R., Bultsma, Y., Keune, W.-J., Halstead, J.R., Elouarrat, D., Mohammed, S., Heck, A.J., (...), Divecha, N.
Nuclear PtdIns5P as a Transducer of Stress Signaling: An In Vivo Role for PIP4Kbeta ([Open Access](#))
(2006) *Molecular Cell*, 23 (5), pp. 685-695. Cited 140 times.
doi: 10.1016/j.molcel.2006.07.014
[View at Publisher](#)
-
- 22 Ciruela, A., Hinchliffe, K.A., Divecha, N., Irvine, R.F.
Nuclear targeting of the β isoform of Type II phosphatidylinositol phosphate kinase (phosphatidylinositol 5-phosphate 4-kinase) by its α -helix 7 ([Open Access](#))
(2000) *Biochemical Journal*, 346 (3), pp. 587-591. Cited 88 times.
doi: 10.1042/0264-6021:3460587
[View at Publisher](#)
-
- 23 Clarke, J.H., Emson, P.C., Irvine, R.F.
Localization of phosphatidylinositol phosphate kinase II γ in kidney to a membrane trafficking compartment within specialized cells of the nephron ([Open Access](#))
(2008) *American Journal of Physiology - Renal Physiology*, 295 (5), pp. F1422-F1430. Cited 43 times.
<http://ajprenal.physiology.org/cgi/reprint/295/5/F1422>
doi: 10.1152/ajprenal.90310.2008
[View at Publisher](#)
-
- 24 Emerling, B.M., Hurov, J.B., Poulogiannis, G., Tsukazawa, K.S., Choo-Wing, R., Wulf, G.M., Bell, E.L., (...), Cantley, L.C.
XDepletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-Null tumors ([Open Access](#))
(2013) *Cell*, 155 (4), p. 844. Cited 99 times.
<https://www.sciencedirect.com/journal/cell>
doi: 10.1016/j.cell.2013.09.057
[View at Publisher](#)
-
- 25 Shim, H., Wu, C., Ramsamooj, S., Bosch, K.N., Chen, Z., Emerling, B.M., Yun, J., (...), Cantley, L.C.
Deletion of the gene Pip4k2c, a novel phosphatidylinositol kinase, results in hyperactivation of the immune system ([Open Access](#))
(2016) *Proceedings of the National Academy of Sciences of the United States of America*, 113 (27), pp. 7596-7601. Cited 20 times.
<http://www.pnas.org/content/113/27/7596.full.pdf>
doi: 10.1073/pnas.1600934113
[View at Publisher](#)
-
- 26 Raychaudhuri, S., Remmers, E.F., Lee, A.T., Hackett, R., Guiducci, C., Burtt, N.P., Gianniny, L., (...), Plenge, R.M.
Common variants at CD40 and other loci confer risk of rheumatoid arthritis ([Open Access](#))
(2008) *Nature Genetics*, 40 (10), pp. 1216-1223. Cited 416 times.
doi: 10.1038/ng.233
[View at Publisher](#)
-

- 27 Dudley, M.E., Wunderlich, J.R., Shelton, T.E., Even, J., Rosenberg, S.A.
Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients ([Open Access](#))
(2003) *Journal of Immunotherapy*, 26 (4), pp. 332-342. Cited 465 times.
doi: 10.1097/00002371-200307000-00005
[View at Publisher](#)
-
- 28 Collison, L.W., Vignali, D.A.
In vitro Treg suppression assays. ([Open Access](#))
(2011) *Methods in molecular biology (Clifton, N.J.)*, 707, pp. 21-37. Cited 88 times.
doi: 10.1007/978-1-61737-979-6_2
[View at Publisher](#)
-
- 29 Ai, W., Li, H., Song, N., Li, L., Chen, H.
Optimal method to stimulate cytokine production and its use in immunotoxicity assessment ([Open Access](#))
(2013) *International Journal of Environmental Research and Public Health*, 10 (9), pp. 3834-3842. Cited 51 times.
<http://www.mdpi.com/1660-4601/10/9/3834/pdf>
doi: 10.3390/ijerph10093834
[View at Publisher](#)
-
- 30 Szabo, S.J., Kim, S.T., Costa, G.L., Zhang, X., Fathman, C.G., Glimcher, L.H.
A novel transcription factor, T-bet, directs Th1 lineage commitment ([Open Access](#))
(2000) *Cell*, 100 (6), pp. 655-669. Cited 2551 times.
www.cell.com
doi: 10.1016/S0092-8674(00)80702-3
[View at Publisher](#)
-
- 31 Yang, X.O., Pappu, B.P., Nurieva, R., Akimzhanov, A., Kang, H.S., Chung, Y., Ma, L., (...), Dong, C.
T Helper 17 Lineage Differentiation Is Programmed by Orphan Nuclear Receptors ROR α and ROR γ ([Open Access](#))
(2008) *Immunity*, 28 (1), pp. 29-39. Cited 1195 times.
doi: 10.1016/j.immuni.2007.11.016
[View at Publisher](#)
-
- 32 Zhu, J., Yamane, H., Cote-Sierra, J., Guo, L., Paul, W.E.
GATA-3 promotes Th2 responses through three different mechanisms: Induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors ([Open Access](#))
(2006) *Cell Research*, 16 (1), pp. 3-10. Cited 272 times.
doi: 10.1038/sj.cr.7310002
[View at Publisher](#)
-
- 33 Chen, W., Jin, W., Hardegen, N., Lei, K.-J., Li, L., Marinos, N., McGrady, G., (...), Wahl, S.M.
Conversion of Peripheral CD4 $^{+}$ CD25 $^{-}$ Naive T Cells to CD4 $^{+}$ CD25 $^{+}$ Regulatory T Cells by TGF- β Induction of Transcription Factor Foxp3 ([Open Access](#))
(2003) *Journal of Experimental Medicine*, 198 (12), pp. 1875-1886. Cited 3560 times.
doi: 10.1084/jem.20030152
[View at Publisher](#)
-
- 34 Matsuoka, K., Inoue, N., Sato, T., Okamoto, S., Hisamatsu, T., Kishi, Y., Sakuraba, A., (...), Hibi, T.
T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction or Th1 mediated immunopathology in Crohn's disease ([Open Access](#))
(2004) *Gut*, 53 (9), pp. 1303-1308. Cited 110 times.
<http://gut.bmjjournals.org/content/by/year>
doi: 10.1136/gut.2003.024190
[View at Publisher](#)

- 35 Hernández-Hoyos, G., Anderson, M.K., Wang, C., Rothenberg, E.V., Alberola-Illia, J.
GATA-3 expression is controlled by TCR signals and regulates CD4/CD8 differentiation ([Open Access](#))
(2003) *Immunity*, 19 (1), pp. 83-94. Cited 194 times.
www.immunity.com
doi: 10.1016/S1074-7613(03)00176-6
[View at Publisher](#)
-
- 36 Williams, L.M., Rudensky, A.Y.
Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3
(2007) *Nature Immunology*, 8 (3), pp. 277-284. Cited 642 times.
doi: 10.1038/ni1437
[View at Publisher](#)
-
- 37 De Simone, M., Arrigoni, A., Rossetti, G., Gruarin, P., Ranzani, V., Politano, C., Bonnal, R.J.P., (...), Pagani, M.
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells ([Open Access](#))
(2016) *Immunity*, 45 (5), pp. 1135-1147. Cited 250 times.
www.immunity.com
doi: 10.1016/j.jimmuni.2016.10.021
[View at Publisher](#)
-
- 38 Miragaia, R.J., Gomes, T., Chomka, A., Jardine, L., Riedel, A., Hegazy, A.N., Whibley, N., (...), Teichmann, S.A.
Single-Cell Transcriptomics of Regulatory T Cells Reveals Trajectories of Tissue Adaptation ([Open Access](#))
(2019) *Immunity*, 50 (2), pp. 493-504.e7. Cited 132 times.
www.immunity.com
doi: 10.1016/j.jimmuni.2019.01.001
[View at Publisher](#)
-
- 39 Chambers, C.A., Kuhns, M.S., Egen, J.G., Allison, J.P.
CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy ([Open Access](#))
(2001) *Annual Review of Immunology*, 19, pp. 565-594. Cited 752 times.
doi: 10.1146/annurev.immunol.19.1.565
[View at Publisher](#)
-
- 40 Jones, D.R., Foulger, R., Keune, W.-J., Bultsma, Y., Divecha, N.
PtdIns5P is an oxidative stress-induced second messenger that regulates PKB activation ([Open Access](#))
(2013) *FASEB Journal*, 27 (4), pp. 1644-1656. Cited 33 times.
<http://www.fasebj.org/content/27/4/1644.full.pdf+html>
doi: 10.1096/fj.12-218842
[View at Publisher](#)
-
- 41 Chi, H.
Regulation and function of mTOR signalling in T cell fate decisions ([Open Access](#))
(2012) *Nature Reviews Immunology*, 12 (5), pp. 325-338. Cited 481 times.
doi: 10.1038/nri3198
[View at Publisher](#)
-
- 42 Liu, C., Chapman, N.M., Karmaus, P.W.F., Zeng, H., Chi, H.
mTOR and metabolic regulation of conventional and regulatory t cells ([Open Access](#))
(2015) *Journal of Leukocyte Biology*, 97 (5), pp. 837-847. Cited 27 times.
<http://www.jleukbio.org/content/97/5/837.full.pdf>
doi: 10.1189/jlb.2R10814-408R
[View at Publisher](#)
-

- 43 Abu-Eid, R., Samara, R.N., Ozbun, L., Abdalla, M.Y., Berzofsky, J.A., Friedman, K.M., Mkrtchyan, M., (...), Khleif, S.N.
Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway ([Open Access](#))
(2014) *Cancer immunology research*, 2 (11), pp. 1080-1089. Cited 95 times.
doi: 10.1158/2326-6066.CIR-14-0095
[View at Publisher](#)
-

- 44 Bostick, M., Jong, K.K., Estève, P.-O., Clark, A., Pradhan, S., Jacobsen, S.E.
UHRF1 plays a role in maintaining DNA methylation in mammalian cells
(2007) *Science*, 317 (5845), pp. 1760-1764. Cited 864 times.
doi: 10.1126/science.1147939
[View at Publisher](#)
-

- 45 Obata, Y., Furusawa, Y., Endo, T.A., Sharif, J., Takahashi, D., Atarashi, K., Nakayama, M., (...), Hase, K.
The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells
(2014) *Nature Immunology*, 15 (6), pp. 571-579. Cited 102 times.
<http://www.nature.com/ni>
doi: 10.1038/ni.2886
[View at Publisher](#)
-

- 46 Helmin, K.A., Morales-Nebreda, L., Torres Acosta, M.A., Anekalla, K.R., Chen, S.-Y., Abdala-Valencia, H., Politanska, Y., (...), Singer, B.D.
Maintenance DNA methylation is essential for regulatory T cell development and stability of suppressive function ([Open Access](#))
(2020) *Journal of Clinical Investigation*, 130 (12). Cited 10 times.
<https://www.jci.org/articles/view/137712/pdf>
doi: 10.1172/JCI137712
[View at Publisher](#)
-

- 47 Gelato, K.A., Tauber, M., Ong, M.S., Winter, S., Hiragami-Hamada, K., Sindlinger, J., Lemak, A., (...), Fischle, W.
Accessibility of different histone H3-binding domains of UHRF1 is allosterically regulated by phosphatidylinositol 5-phosphate ([Open Access](#))
(2014) *Molecular Cell*, 54 (6), pp. 905-919. Cited 78 times.
www.molecule.org
doi: 10.1016/j.molcel.2014.04.004
[View at Publisher](#)
-

- 48 Clarke, J.H., Giudici, M.-L., Burke, J.E., Williams, R.L., Maloney, D.J., Marugan, J., Irvine, R.F.
The function of phosphatidylinositol 5-phosphate 4-kinase γ (Pi5p4Kγ) explored using a specific inhibitor that targets the PI5P-binding site ([Open Access](#))
(2015) *Biochemical Journal*, Part 2 466, pp. 359-367. Cited 16 times.
<http://www.biochemj.org/bj/466/0359/4660359.pdf>
doi: 10.1042/BJ20141333
[View at Publisher](#)
-

- 49 Wang, D.G., Paddock, M.N., Lundquist, M.R., Sun, J.Y., Mashadova, O., Amadiume, S., Bumpus, T.W., (...), Cantley, L.C.
PIP4Ks Suppress Insulin Signaling through a Catalytic-Independent Mechanism ([Open Access](#))
(2019) *Cell Reports*, 27 (7), pp. 1991-2001.e5. Cited 8 times.
<http://www.sciencedirect.com/science/journal/22111247>
doi: 10.1016/j.celrep.2019.04.070
[View at Publisher](#)
-

- 50 Carricaburu, V., Lamia, K.A., Lo, E., Favereaux, L., Payrastre, B., Cantley, L.C., Rameh, L.E. The phosphatidylinositol (PI)-5-phosphate 4-kinase type II enzyme controls insulin signaling by regulating PI-3,4,5-trisphosphate degradation ([Open Access](#))
(2003) *Proceedings of the National Academy of Sciences of the United States of America*, 100 (17), pp. 9867-9872. Cited 90 times.
doi: 10.1073/pnas.1734038100
[View at Publisher](#)
-

- 51 Ramel, D., Lagarrigue, F., Dupuis-Coronas, S., Chicanne, G., Leslie, N., Gaits-Iacovoni, F., Payrastre, B., (...), Tronchère, H. PtdIns5P protects Akt from dephosphorylation through PP2A inhibition
(2009) *Biochemical and Biophysical Research Communications*, 387 (1), pp. 127-131. Cited 24 times.
doi: 10.1016/j.bbrc.2009.06.139
[View at Publisher](#)
-
- 52 Stijf-Bultsma, Y., Sommer, L., Tauber, M., Baalbaki, M., Giardoglou, P., Jones, D.R., Gelato, K.A., (...), Divecha, N. The basal transcription complex component TAF3 transduces changes in nuclear phosphoinositides into transcriptional output ([Open Access](#))
(2015) *Molecular Cell*, 58 (3), pp. 453-467. Cited 32 times.
www.molecule.org
doi: 10.1016/j.molcel.2015.03.009
[View at Publisher](#)
-

- 53 Ohkura, N., Kitagawa, Y., Sakaguchi, S. Development and Maintenance of Regulatory T cells ([Open Access](#))
(2013) *Immunity*, 38 (3), pp. 414-423. Cited 489 times.
doi: 10.1016/j.jimmuni.2013.03.002
[View at Publisher](#)
-

- 54 Sun, X., Cui, Y., Feng, H., Liu, H., Liu, X. TGF-β signaling controls Foxp3 methylation and T reg cell differentiation by modulating Uhrf1 activity ([Open Access](#))
(2019) *Journal of Experimental Medicine*, 216 (12), pp. 2819-2837. Cited 16 times.
<http://jem.rupress.org/content/by/year>
doi: 10.1084/jem.20190550
[View at Publisher](#)
-

- 55 Helmin, K.A., Morales-Nebreda, L., Torres Acosta, M.A., Anekalla, K.R., Chen, S.-Y., Abdala-Valencia, H., Politanska, Y., (...), Singer, B.D. Maintenance DNA methylation is essential for regulatory T cell development and stability of suppressive function ([Open Access](#))
(2020) *Journal of Clinical Investigation*, 130 (12). Cited 10 times.
<https://www.jci.org/articles/view/137712/pdf>
doi: 10.1172/JCI137712
[View at Publisher](#)
-

- 56 Wang, L., Liu, Y., Beier, U.H., Han, R., Bhatti, T.R., Akimova, T., Hancock, W.W. Foxp3+ T-regulatory cells require DNA methyltransferase 1 expression to prevent development of lethal autoimmunity ([Open Access](#))
(2013) *Blood*, 121 (18), pp. 3631-3639. Cited 44 times.
<http://bloodjournal.org/content/121/18/3631.full-text.pdf+html>
doi: 10.1182/blood-2012-08-451765
[View at Publisher](#)
-

- 57 Alhosin, M., Omran, Z., Zamzami, M.A., Al-Malki, A.L., Choudhry, H., Mousli, M., Bronner, C.
Signalling pathways in UHRF1-dependent regulation of tumor suppressor genes in cancer ([Open Access](#))
(2016) *Journal of Experimental and Clinical Cancer Research*, 35 (1), pp. 1-11. Cited 51 times.
<http://www.jeccr.com/>
doi: 10.1186/s13046-016-0453-5
[View at Publisher](#)
-
- 58 Jude, J.G., Spencer, G.J., Huang, X., Somerville, T.D.D., Jones, D.R., Divecha, N., Somervaille, T.C.P.
A targeted knockdown screen of genes coding for phosphoinositide modulators identifies PIP4K2A as required for acute myeloid leukemia cell proliferation and survival ([Open Access](#))
(2015) *Oncogene*, 34 (10), pp. 1253-1262. Cited 39 times.
<http://www.nature.com/onc/index.html>
doi: 10.1038/onc.2014.77
[View at Publisher](#)
-

- 59 Kitagawa, M., Liao, P.-J., Lee, K.H., Wong, J., Shang, S.C., Minami, N., Sampetrean, O., (...), Lee, S.H.
Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality ([Open Access](#))
(2017) *Nature Communications*, 8 (1), art. no. 2200. Cited 36 times.
<http://www.nature.com/ncomms/index.html>
doi: 10.1038/s41467-017-02287-5
[View at Publisher](#)
-
- 60 Manz, T.D., Sivakumaren, S.C., Ferguson, F.M., Zhang, T., Yasgar, A., Seo, H.-S., Ficarro, S.B., (...), Gray, N.S.
Discovery and structure-activity relationship study of (z)-5-methylenethiazolidin-4-one derivatives as potent and selective pan-phosphatidylinositol 5-phosphate 4-kinase inhibitors ([Open Access](#))
(2020) *Journal of Medicinal Chemistry*, 63 (9), pp. 4880-4895. Cited 3 times.
<http://pubs.acs.org/jmc>
doi: 10.1021/acs.jmedchem.0c00227
[View at Publisher](#)

✉ Poli, A.; Italian Foundation for Cancer Research Institute of Molecular Oncology, Milan, Italy;
email:alessandro.poli@ifom.eu

✉ Divecha, N.; National Institute of Molecular Genetics "Romeo ed Enrica Invernizzi", Milan, Italy;
email:nd1m13@soton.ac.uk

© Copyright 2021 Elsevier B.V. All rights reserved.

[« Back to results](#) | 1 of 1

[^ Top of page](#)

About Scopus

- [What is Scopus](#)
- [Content coverage](#)
- [Scopus blog](#)
- [Scopus API](#)
- [Privacy matters](#)

Language

- [日本語に切り替える](#)
- [切换到简体中文](#)
- [切換到繁體中文](#)
- [Русский язык](#)

Customer Service

- [Help](#)
- [Contact us](#)

ELSEVIER

[Terms and conditions](#) ↗ [Privacy policy](#) ↗

Copyright © Elsevier B.V. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

 RELX